M6PR

Across TCGA pan-cancer cohorts, M6PR Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated M6PR data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher M6PR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated M6PR expression acts as an unfavorable survival marker.

STAD and PRAD are the cancer types where M6PR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.667	<.001	36	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

M6PR–STAD (OS)

Open the STAD breakdown →